A comparison of the effects of Triamcinolone and Dexmedetomidine in caudal neuroplasty in chronic low back pain.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111102007984N28

Enrollment

Registered

2018-12-17

Start date

2017-09-23

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

low back pain. Low back pain

Interventions

Intervention 1: Intervention group: In intervention group 10ml Ropivacaine 0.2%, 50mg Dexmedetomidine (Excir, Iran) and was injected in the caudal epidural space by a catheter under fluoroscopy. Inte

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Chronic low back pain more than six months +/- radiculopathy, 2) Moderate to severe pain score (> 3, based on the Visual Analog Scale),3) Age 40-70 years,4) Inadequate response to conservative and physiotherapy treatments after three months,5) ASA classification I-II,6) Disc protrusion (at MRI)

Exclusion criteria

Exclusion criteria: 1) Severe canal stenosis (more than two thirds in axial MRI view), 2) Sequestrated disc (fragmented),3) Decreased disc height more than 60%,4) Sever spinal deformity,5) Spinal tumors,6) Vertebral fracture,7) Spondylolisthesis > Grade II, 8) Local or systemic infection, 9) Taking anticoagulants,10) Drug abuse,11) History of drug reaction,12) Sever psychological disorders,13) Pregnancy and lactation,14) Severe or sudden neurological deficit such as urinary or fecal incontinence,15) Body Mass Index (BMI) > 35,16) Patient's refusal,17) Diabetes mellitus, 18) MRI contraindications (cardiac pacemaker, defibrillator, aortic aneurysm clips),19)Impossible prone positioning

Design outcomes

Primary

Measure	Time frame
Low back pain. Timepoint: Before injection,two weeks,1,3 and 6 month after intervention. Method of measurement: pain score measured with visual analogue scale in Questionnaire.	—

Secondary

Measure	Time frame
Oswestry Disability Index questionnaire (ODI) and straight leg raising test (SLR), Reverse straight leg raising test (RSLR),Bonnet,FABER,Gaenslen,Tiptoe and Heel walking,analgesic consumption,blood sugar,HbA1C,MRI. Timepoint: Before injection, two weeks, 1,3 and 6 moth after intervention. Blood sugar ,before injection,2 th day and 2th week after injectionHbA1C, before injection,3 and 6 month after injection MRI, before injection and 6 month after injection. Method of measurement: Questionnaire.	—

Measure

Time frame

Oswestry Disability Index questionnaire (ODI) and straight leg raising test (SLR), Reverse straight leg raising test (RSLR),Bonnet,FABER,Gaenslen,Tiptoe and Heel walking,analgesic consumption,blood sugar,HbA1C,MRI. Timepoint: Before injection, two weeks, 1,3 and 6 moth after intervention. Blood sugar ,before injection,2 th day and 2th week after injectionHbA1C, before injection,3 and 6 month after injection MRI, before injection and 6 month after injection. Method of measurement: Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarnad Imani

Iran University of Medical Sciences

farnadimani@yahoo.com+98 21 6651 5758

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026